{"id":"W2768057131","doi":"10.1093/neuonc/nox168.058","title":"ACTR-71. FULL ENROLLMENT RESULTS FROM THE PHASE 1/2, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) ± BEVACIZUMAB (BEV) IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, RGBM)","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Glioma; Lethargy; Bevacizumab; Adverse effect; Internal medicine; Phases of clinical research; Surgery; Gastroenterology; Toxicity; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001595421,0.001665621,0.001788574,0.0004101355,0.0006329851,0.0008268806,0.0009141823,0.001172647,0.01816122],"category_scores_gemma":[0.0006749457,0.0005441744,0.0006983684,0.0004697113,0.0004267378,0.0005530374,0.0003279905,0.002362491,0.006913499],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008454476,"about_ca_system_score_gemma":0.002472824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001295065,"about_ca_topic_score_gemma":0.003762853,"domain_scores_codex":[0.9993278,0.0002695926,0.00003325811,0.00009077746,0.000116303,0.0001624078],"domain_scores_gemma":[0.9995466,0.0000515031,0.00005415478,0.0000326116,0.00004682975,0.0002683994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4344271,0.05659786,0.006896053,0.001645962,0.0009823577,0.0006379585,0.0003450964,0.003011215,0.1158705,0.000808797,0.103344,0.2754331],"study_design_scores_gemma":[0.5307574,0.3277388,0.04004153,0.0001035429,0.0009028082,0.001243765,0.00008788126,0.001695305,0.01537697,0.000400518,0.08156458,0.00008687712],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8898042,0.006010487,0.003009113,0.001919941,0.0005664006,0.01732058,0.04924807,0.001841084,0.03028014],"genre_scores_gemma":[0.8549148,0.004127684,0.005722036,0.004039752,0.000527475,0.01539696,0.07798829,0.0004389798,0.03684395],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01816122,"threshold_uncertainty_score":0.06075531,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0698189916436657,"score_gpt":0.3799224895923255,"score_spread":0.3101034979486598,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}